echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Rivus dinitrophenol prodrug HU6 phase II clinical success

    Rivus dinitrophenol prodrug HU6 phase II clinical success

    • Last Update: 2022-03-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    news

    news

    Today Rivus announced that its dinitrophenol (DNP) prodrug, HU6, achieved a primary endpoint in a Phase II trial in fatty liver disease
    .


    This trial enrolled 80 obese patients with fatty liver and compared the effect of three doses of HU6 and placebo on liver fat content


    Drug source analysis

    Drug source analysis

    Rivus received $35 million in Series A backing from Longitude, Medicxi, and Rx Capital last year, and HU6 appears to have been acquired from Sanyal
    .


    Rivus' technology platform is called controlled metabolic accelerators (CMAs), and HU6 is a core asset that has entered early clinical trials for type 2 diabetes, NASH, severe hypertriglyceridemia, and heart failure (HFpEF)


    The chemical structure of HU6 has not been published, so it is not known how the release of the original drug is controlled by feedback
    .


    DNP is a mitochondrial decoupling agent, which can convert the energy generated by mitochondrial oxidation into heat energy and accelerate energy consumption


    DNP has a super fat-burning ability and has been verified on a large scale in the human body, but its safety is very poor
    .


    So DNP is similar to the highly toxic warhead in the ADC design, but it's just a metabolic warhead


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.